Introduction
Potassium clorazepate is a tranquilliser of the benzodiazepine group which has had no serious toxic effects reported to date. A case ofjaundice and hepatic necrosis, probably due to this drug, is now described.
Case report
A 27-year-old man presented to a psychiatric hospital for 3 months and a course of electroconvulsive therapy was given followed by treatment with L-tryptophan and phenelzine.
Histology of liver biopsies 1. February 1977 (Fig. 1) . This showed mild centrilobular cholestasis. In addition, there was focal' liver cell necrosis, single cell eosinophilic necrosis and reactive Kupffer cell hyperplasia. The most striking changes involved the portal tracts which were markedly swollen and oedematous with extension of their young fibrous tissue septa, producing portal-portal bridging. Within the portal tracts and fibrous septa there was a marked, mainly ,') , \ a. mononuclear cell infiltrate. This was predominantly lymphocytes, but small numbers of plasma cells, pigment-laden macrophages and a few eosinophils were also noted. At the fibrous/parenchymal interface there was conspicuous ductal proliferation with spillover of inflammatory cells into the adjacent parenchyma.
2. May 1977 (Fig. 2) . Apart from some prominence of ceroid-containing Kupffer cells the parenchyma was unremarkable. The portal inflammation was considerably less than in the first biopsy. There was, however, well marked fine fibrous septa formation producing portal-portal linkage and a monolobular fibrotic pattern. Parenchymal ductal proliferation persisted especially within some portal areas.
3. July 1977 (Fig. 3 ). There was a moderate degree of centrilobular macrovesicular steatosis. Thin fibrous septa persisted with well defined portalportal bridging. There was a mild residual chronic inflammatory cell infiltrate in the portal tract, focally intense in some, but with no evidence of spillover into the parenchyma and with now no evident ductular proliferation.
Discussion
The temporal relationship between ingestion of clorazepate and development of liver dysfunction suggests a cause-and-effect relationship. The manufacturers have no reports of liver damage due to clorazepate but the Committee on Safety of Medicines have 2 recorded instances of jaundice (personal communication, 1977) . Those patients, of course, may have been receiving more than one drug at the time.
The clorazepate was continued for 6 weeks after the appearance of the jaundice, and it is disturbing that there is persistence of the residual monolobular pattern of fibrosis 6 months after stopping the drug. Whether the patient will go on to develop a true cirrhosis is uncertain.
It is suggested that this drug should not be given to patients with any evidence of hepatic dysfunction, and should be discontinued as soon as jaundice is observed.
